Recently, inhibition of the enzyme lysyl oxidase-like 2 (LOXL2) by a humanized monoclonal antibody (simtuzumab) has been attempted in colorectal and pancreatic cancers in combination with FOLFIRI or gemcitabine, respectively [185,186]. Here, LOXL2 is linked to familial pancreatic carcinoma.